Medtronic PLC (NYSE:MDT) Receives Consensus Rating of “Moderate Buy” from Analysts

Medtronic PLC (NYSE:MDT) has been given an average recommendation of “Moderate Buy” by the twenty-seven research firms that are currently covering the company, Marketbeat Ratings reports. Ten research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $98.9583.

A number of brokerages have weighed in on MDT. Deutsche Bank Aktiengesellschaft cut their target price on shares of Medtronic from $100.00 to $78.00 and set a “hold” rating on the stock in a research report on Thursday, June 4th. Leerink Partners lowered their price target on shares of Medtronic from $117.00 to $104.00 and set an “outperform” rating for the company in a report on Thursday, June 4th. Truist Financial dropped their price target on Medtronic from $95.00 to $86.00 and set a “hold” rating for the company in a research note on Thursday, June 4th. The Goldman Sachs Group cut their price objective on Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a report on Thursday, June 4th. Finally, Evercore set a $105.00 price objective on Medtronic in a research report on Monday.

Insider Buying and Selling at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the sale, the executive vice president owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. This represents a 10.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.26% of the company’s stock.

Institutional Trading of Medtronic

Large investors have recently modified their holdings of the stock. Lodestone Wealth Management LLC acquired a new stake in Medtronic in the fourth quarter worth $27,000. Anfield Capital Management LLC raised its holdings in shares of Medtronic by 410.7% during the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 230 shares during the period. Monetary Solutions Ltd bought a new position in shares of Medtronic during the 4th quarter worth about $27,000. Board of the Pension Protection Fund bought a new position in shares of Medtronic during the 4th quarter worth about $29,000. Finally, GoalVest Advisory LLC acquired a new stake in shares of Medtronic in the 4th quarter valued at about $29,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Down 2.1%

Shares of NYSE MDT opened at $82.06 on Thursday. The company has a market cap of $105.04 billion, a price-to-earnings ratio of 22.00, a PEG ratio of 2.25 and a beta of 0.56. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52. Medtronic has a 12 month low of $73.31 and a 12 month high of $106.33. The stock has a 50-day moving average price of $79.01 and a two-hundred day moving average price of $88.67.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. The company had revenue of $9.81 billion for the quarter, compared to the consensus estimate of $9.62 billion. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The firm’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period last year, the company posted $1.62 EPS. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. As a group, analysts forecast that Medtronic will post 5.94 earnings per share for the current fiscal year.

Medtronic Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 17th. Investors of record on Friday, June 26th will be issued a $0.72 dividend. The ex-dividend date is Friday, June 26th. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 dividend on an annualized basis and a yield of 3.5%. Medtronic’s dividend payout ratio (DPR) is currently 77.21%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).